ArticleFrontiers in oncology2026
Renal inflammatory myofibroblastic tumor: a case report.
Article in Frontiers in oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Objective: To investigate potential diagnostic approaches and therapeutic strategies for renal inflammatory myofibroblastic tumors (IMT). Methods: Renal IMT is a rare mesenchymal neoplasm with intermediate malignant potential arising within the urinary system. Its clinical presentation and imaging characteristics are nonspecific; thus, histopathological examination remains the diagnostic gold standard. This article presents a retrospective analysis of the clinical course of a single patient diagnosed with renal IMT. Patient: An elderly female presented with intermittent abdominal pain. Abdominal contrast-enhanced computed tomography (CT) revealed a solid mass located in the anterior lip of the right kidney. Following radical right nephrectomy, histopathological evaluation confirmed the diagnosis of renal IMT. Results: At the 3- and 6-month follow-up visits postoperatively, the patient showed no evidence of local recurrence or distant metastasis. Conclusion: Definitive diagnosis of renal IMT relies exclusively on histopathological assessments. For localized disease, complete surgical resection, preferably radical nephrectomy, is the treatment of choice. In advanced or unresectable cases, tyrosine kinase inhibitors and other targeted agents may be considered as potential therapeutic options.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.